Bentue-FerrerD, ArvieuxC, TributO, RuffaultA, BellissantE. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opin Drug Metab Toxicol, 2009; 5:1455–1468.
2.
SanneI, PilieroP, SquiresK, ThiryA, SchnittmanS. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr, 2003; 32:18–29.
3.
SquiresK, LazzarinA, GatellJM, PowderlyWG, PokrovskiyV, DelfraissyJFet al.Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr, 2004; 36:1011–1019.
4.
WoodR, PhanuphakP, CahnP, PokrovskiyV, RozenbaumW, PantaleoGet al.Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr, 2004; 36:684–692.
5.
JohnsonM, GrinsztejnB, RodriguezC, CocoJ, DeJesusE, LazzarinAet al.Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS, 2005; 19:153–162.
6.
MolinaJM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs, 2008; 68:567–578.
7.
TortiC, LapadulaG, AntinoriA, QuirinoT, MaseratiR, CastelnuovoFet al.Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection, 2009; 37:244–249.
8.
MalanDR, KrantzE, DavidN, WirtzV, HammondJ, McGrathD. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr, 2008; 47:161–167.
9.
MurphyRL, SanneI, CahnP, PhanuphakP, PercivalL, KelleherT, GiordanoM. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS, 2003; 17:2603–2614.
10.
OrrickJJ, SteinhartCR. Atazanavir. Ann Pharmacother, 2004; 38:1664–1674.
11.
WoodR. Atazanavir: Its role in HIV treatment. Expert Rev Anti Infect Ther, 2008; 6:785–796.
12.
LankischTO, MoebiusU, WehmeierM, BehrensG, MannsMP, SchmidtRE, StrassburgCP. Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. Hepatology, 2006; 44:1324–1332.
13.
RotgerM, TaffeP, BleiberG, GunthardHF, FurrerH, VernazzaPet al.Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis, 2005; 192:1381–1386.
14.
Rodriguez NovoaS, BarreiroP, RendonA, BarriosA, CorralA, Jimenez-NacherIet al.Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis, 2006; 42:291–295.
